e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2026; 18(3); 1233-1243

Original Research Article

Targeted Therapy for Oral Squamous Cell Carcinoma: Emerging Therapeutic Strategies and Clinical Perspectives

Praveen S. Anigol[1], Vijayalakshmi Kotrashetti[2], Kishore G. Bhat[3], Bhagyashri N. Vanaki[4]

[1]M.D.S., Professor, Department of Oral Pathology and Microbiology, P.M.N.M. Dental College and Hospital, Navanagar, Bagalkot – 587103, Karnataka, India
[2]M.D.S., Professor & Head Of Department, Department of Oral Pathology and Microbiology, Maratha Mandal's Nathajirao G. Halgekar Institute of Dental Sciences &Research Centre #47 A/2, Near KSRP Ground, Bauxite Road, Belagavi - 590010, Karnataka, India
[3]M.D., Director, Department of Microbiology, Arihant Hospitals, Belagavi, Karnataka, India
[4]M.D.S, Professor, Department of Periodontics, P.M.N.M. Dental College and Hospital, Navanagar, Bagalkot – 587103 Karnataka, India

Received: 26-01-2026 / Revised: 25-02-2026 / Accepted: 27-03-2026
Corresponding Author: Dr. Praveen S. Anigol
Conflict of interest: Nil

Abstract:

Oral squamous cell carcinoma (OSCC) represents a significant global health burden with limited therapeutic options beyond conventional surgery, radiotherapy, and chemotherapy. The molecular characterization of OSCC has revealed numerous dysregulated signaling pathways, providing opportunities for targeted therapeutic intervention. This review comprehensively examines emerging targeted therapies for OSCC, focusing on novel agents and their molecular mechanisms. Epidermal growth factor receptor (EGFR) inhibitors, including cetuximab, gefitinib, and erlotinib, have demonstrated clinical efficacy, with cetuximab showing improved overall survival when combined with radiotherapy or chemotherapy. Immune checkpoint inhibitors targeting PD-1/PD-L1, such as pembrolizumab and nivolumab, have revolutionized treatment paradigms for recurrent or metastatic disease. The PI3K/AKT/mTOR pathway represents another promising target, with multiple inhibitors under investigation. MEK inhibitors like trametinib have shown encouraging results in neoadjuvant settings, achieving significant tumor responses. Novel targets including STAT3, VEGFR, dual tyrosine kinase inhibitors, and epigenetic modulators are emerging as potential therapeutic options. Despite these advances, challenges remain, including primary and acquired resistance, tumor heterogeneity, limited biomarker validation, and the need for personalized treatment strategies. Clinical trials have demonstrated variable response rates and modest survival benefits, highlighting the complexity of OSCC biology. Future directions include combination therapies, identification of predictive biomarkers, development of novel delivery systems, and integration of multi-omics approaches for patient stratification. This review synthesizes current evidence on emerging targeted therapies, providing insights into molecular mechanisms, clinical outcomes, and future research priorities for improving OSCC patient outcomes.

Keywords: Oral Squamous Cell Carcinoma, Targeted Therapy, EGFR Inhibitors, Immunotherapy, PI3K/mTOR Pathway, MEK Inhibitors, Precision Medicine.

DOI: 10.25258/ijcpr.18.3.197

Introduction

Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of all oral malignancies and represents a major cause of cancer-related morbidity and mortality worldwide [1], [2]. Despite advances in surgical techniques, radiotherapy, and chemotherapy, the five-year survival rate for OSCC remains approximately 50-60%, with limited improvement over the past several decades [3], [4]. The poor prognosis is attributed to late-stage diagnosis, locoregional recurrence, distant metastasis, and resistance to conventional therapies [5], [6]. These challenges have necessitated the development of novel therapeutic strategies that target specific molecular alterations driving OSCC pathogenesis.

The molecular characterization of OSCC has revealed a complex landscape of genetic and epigenetic alterations, including mutations in key oncogenes and tumor suppressor genes, dysregulation of signaling pathways, and alterations in the tumor microenvironment [7], [8]. These

molecular insights have identified numerous potential therapeutic targets and have paved the way for the development of targeted therapies that aim to selectively inhibit oncogenic pathways while sparing normal tissues [9], [10]. Targeted therapies offer the promise of improved efficacy and reduced toxicity compared to conventional cytotoxic chemotherapy.

This review provides a comprehensive examination of emerging targeted therapies for OSCC, with a focus on novel agents currently under investigation or in clinical use. We discuss the molecular mechanisms underlying these therapies, their clinical efficacy and safety profiles, and the challenges that must be addressed to optimize their therapeutic potential. Additionally, we explore future directions in the field, including combination strategies, biomarker development, and personalized medicine approaches.

Molecular Mechanisms and Dysregulated Pathways in OSCC (Table:1): The development and progression of OSCC are driven by the accumulation of genetic and epigenetic alterations that dysregulate critical cellular processes, including cell proliferation, survival, differentiation, invasion, and metastasis [11], [12]. Understanding these molecular mechanisms is essential for identifying therapeutic targets and developing rational treatment strategies.

One of the most frequently dysregulated pathways in OSCC is the epidermal growth factor receptor (EGFR) signaling pathway. EGFR is a receptor tyrosine kinase that, upon ligand binding, activates downstream signaling cascades, including the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways [13], [14]. EGFR is overexpressed and activated in the majority of OSCC cases, and its activation promotes cell proliferation, survival, invasion, and angiogenesis [15], [16]. The frequent dysregulation of EGFR signaling has made it a primary target for therapeutic intervention.

The PI3K/AKT/mTOR pathway is another critical signaling cascade frequently altered in OSCC. This pathway regulates cell growth, metabolism, and survival, and its dysregulation is often driven by mutations in PIK3CA (encoding the p110α catalytic subunit of PI3K), loss of PTEN (a negative regulator of PI3K signaling), or amplification of AKT [17], [18]. Activation of the PI3K/AKT/mTOR pathway contributes to tumor cell survival, proliferation, and resistance to apoptosis, making it an attractive target for therapeutic intervention.

The RAS/RAF/MEK/ERK pathway, also known as the MAPK pathway, is frequently activated in OSCC due to mutations in RAS family genes or activation of upstream receptors such as EGFR [19], [20]. This pathway plays a central role in regulating cell proliferation and survival, and its dysregulation contributes to oncogenesis and tumor progression.

TP53, encoding the tumor suppressor protein p53, is the most frequently mutated gene in OSCC [21], [22]. Loss of p53 function disrupts cell cycle regulation, apoptosis, and DNA repair, leading to genomic instability and resistance to therapy. The high frequency of TP53 mutations in OSCC presents both challenges and opportunities for therapeutic intervention.

Other dysregulated pathways in OSCC include the NOTCH signaling pathway, which plays complex and context-dependent roles in OSCC pathogenesis [23], [24], and immune evasion mechanisms, including upregulation of immune checkpoint molecules such as PD-L1, which suppress anti-tumor immune responses [25], [26].

Table 1: Key Dysregulated Signaling Pathways in OSCC

Pathway Name	Key Molecules/Proteins	Alterations in OSCC	Downstream Effects	Therapeutic Implications
EGFR Signaling	EGFR (Epidermal Growth Factor Receptor)	Overexpression and activation in majority of OSCC cases	Activation of downstream PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways; promotes cell proliferation, survival, invasion	Primary target for therapeutic intervention; multiple EGFR inhibitors developed
PI3K/AKT/mTOR Pathway	PIK3CA, PTEN, AKT, mTOR	PIK3CA mutations (frequent), PTEN loss, AKT amplification	Regulates cell growth, metabolism, survival	Critical pathway for targeted therapy; multiple inhibitors under investigation
RAS/RAF/MEK/ERK Pathway	RAS, RAF, MEK, ERK	Mutations in RAS family genes, upstream	Promotes cell proliferation and survival	Target for MEK inhibitors; combination

		receptor activation		strategies explored
TP53 Pathway	TP53 (tumor suppressor gene)	TP53 mutations (most frequently mutated gene in OSCC)	Loss of cell cycle regulation, apoptosis, DNA repair	Contributes to genomic instability, therapeutic resistance
NOTCH Signaling	NOTCH receptors and ligands	Dysregulation (context-dependent: oncogenic or tumor-suppressive roles)	Regulates cell fate decisions, differentiation, proliferation	Complex role requires further investigation
Immune Evasion Mechanisms	PD-L1, immune checkpoint molecules	PD-L1 expression on tumor cells and immune cells	Suppresses anti-tumor immune responses	Target for immune checkpoint inhibitors (pembrolizumab, nivolumab)

Emerging Targeted Agents

EGFR Inhibitors (Table:2): EGFR inhibitors represent one of the most extensively studied classes of targeted therapies for OSCC. Given the frequent overexpression and activation of EGFR in OSCC, inhibition of this receptor has been a logical therapeutic strategy [27], [28]. EGFR inhibitors can be broadly classified into two categories: monoclonal antibodies that bind to the extracellular domain of EGFR and small molecule tyrosine kinase inhibitors (TKIs) that target the intracellular kinase domain.

Cetuximab, a chimeric monoclonal antibody that binds to the extracellular domain of EGFR, has demonstrated clinical efficacy in head and neck squamous cell carcinoma (HNSCC), including OSCC [29], [30]. Cetuximab blocks ligand binding to EGFR, preventing receptor activation and downstream signaling. Clinical trials have shown that cetuximab, in combination with radiotherapy or chemotherapy, improves overall survival in patients with recurrent or metastatic HNSCC [31], [32].

Small molecule EGFR TKIs, such as gefitinib and erlotinib, have also been investigated in OSCC. These agents inhibit the tyrosine kinase activity of EGFR, thereby blocking downstream signaling pathways. However, clinical trials of EGFR TKIs in OSCC have yielded variable results, with limited clinical efficacy observed in unselected patient populations [33], [34].

Despite the promise of EGFR inhibitors, primary and acquired resistance mechanisms limit their therapeutic efficacy. Resistance mechanisms include activation of alternative signaling pathways (e.g., PI3K/AKT, STAT3), mutations in EGFR that reduce drug binding, and upregulation of other receptor tyrosine kinases (RTKs) [35], [36]. Understanding and overcoming this resistance mechanisms remain critical challenges in the field.

Table 2: EGFR Inhibitors in OSCC

Drug/Agent	Molecular Target	Mechanism of Action	Clinical Trial Phase/Setting	Patient Population	Outcomes/ Results	Limitations/ Notes
Cetuximab	EGFR	Monoclonal antibody that binds to EGFR extracellular domain, blocking ligand binding and receptor activation	Clinical trials	Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)	Improved overall survival when combined with radiotherapy or chemotherapy	Most extensively studied; clinical efficacy demonstrated
Gefitinib	EGFR	Small molecule tyrosine	Under investigation	OSCC patients	Variable responses observed	Limited clinical efficacy in

		kinase inhibitor				unselected patient populations
Erlotinib	EGFR	Small molecule tyrosine kinase inhibitor	Under investigation	OSCC patients	Variable responses observed	Limited clinical efficacy in unselected patient populations

Immunotherapy and Immune Checkpoint Inhibitors (Table:3): Immunotherapy has emerged as a transformative approach in cancer treatment, harnessing the power of the immune system to recognize and eliminate tumor cells [37], [38]. In OSCC, immune checkpoint inhibitors targeting the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) axis have shown promising clinical activity [39], [40].

PD-1 is an inhibitory receptor expressed on T cells, and its interaction with PD-L1, which is often upregulated on tumor cells and immune cells within the tumor microenvironment, leads to T cell exhaustion and immune evasion [41], [42]. Blocking the PD-1/PD-L1 interaction with monoclonal antibodies restores anti-tumor immune responses and has demonstrated clinical efficacy in various cancers, including OSCC.

Pembrolizumab and nivolumab, both anti-PD-1 monoclonal antibodies, have been approved for the treatment of recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy [43], [44]. Clinical trials have demonstrated durable responses and improved survival in a subset of patients treated with these agents [45], [46]. However, response rates remain modest (approximately 15-20% in unselected populations), and there is a critical need for predictive biomarkers to identify patients most likely to benefit from immunotherapy.

PD-L1 expression, as assessed by immunohistochemistry, has been explored as a predictive biomarker, but its utility is limited by variability in assay methodologies, cutoff values, and the dynamic nature of PD-L1 expression [47], [48]. Other potential biomarkers, including tumor mutational burden (TMB), microsatellite instability (MSI), and immune gene signatures, are under investigation [49], [50].

Combination strategies, including the use of immune checkpoint inhibitors in combination with chemotherapy, radiotherapy, or other targeted agents, are being actively explored to enhance response rates and overcome resistance mechanisms.

Table 3: Immune Checkpoint Inhibitors in OSCC

Drug/Agent	Molecular Target	Mechanism of Action	Clinical Trial Phase/ Setting	Patient Population	Outcomes/ Results	Clinical Significance
Pembrolizumab	PD-1	Monoclonal antibody blocking PD-1/PD-L1 interaction	FDA approved	Recurrent or metastatic HNSCC with disease progression on/after platinum-containing chemotherapy	Demonstrated durable responses and improved survival	Revolutionized treatment paradigms for recurrent or metastatic disease
Nivolumab	PD-1	Monoclonal antibody blocking PD-1/PD-L1 interaction	FDA approved	Recurrent or metastatic HNSCC with disease progression on/after platinum-containing chemotherapy	Demonstrated durable responses and improved survival	Revolutionized treatment paradigms for recurrent or metastatic disease

PI3K/AKT/mTOR Pathway Inhibitors (Table:4): The PI3K/AKT/mTOR pathway is frequently dysregulated in OSCC, making it an attractive target for therapeutic intervention. Inhibitors targeting various components of this pathway, including PI3K, AKT, and mTOR, have been developed and are being evaluated in preclinical and clinical studies.

PI3K inhibitors target the catalytic subunits of PI3K, thereby blocking the activation of downstream signaling molecules such as AKT and mTOR. Several PI3K inhibitors, including pan-PI3K inhibitors and isoform- specific inhibitors, have been investigated in OSCC. However, clinical development has been hampered by dose-limiting toxicities and modest single-agent activity.

AKT inhibitors directly target the AKT kinase, a central node in the PI3K/AKT/mTOR pathway. Preclinical studies have demonstrated that AKT inhibition can suppress tumor growth and induce apoptosis in OSCC cells. Clinical trials of AKT inhibitors in OSCC are ongoing, with early results suggesting potential clinical benefit in selected patient populations.

mTOR inhibitors, such as rapamycin and its analogs (rapalogs), have been extensively studied in various cancers. mTOR is a serine/threonine kinase that regulates cell growth, proliferation, and metabolism. Inhibition of mTOR has shown preclinical efficacy in OSCC models, but clinical trials have yielded mixed results, with modest single-agent activity observed.

Combination approaches, including the use of PI3K/AKT/mTOR inhibitors in combination with other targeted agents or chemotherapy, are being explored to enhance efficacy and overcome resistance mechanisms.

Table 4: PI3K/AKT/mTOR Pathway Inhibitors in OSCC

Inhibitor Type	Specific Agents/Examples	Molecular Target	Development Status	Clinical Findings	Limitations/Challenges
PI3K inhibitors	Multiple agents	PI3K	Under investigation	Being evaluated in preclinical and clinical studies	Dose-limiting toxicities, modest single-agent activity
AKT inhibitors	Multiple agents	AKT	Under investigation	Being evaluated in preclinical and clinical studies	Dose-limiting toxicities, modest single-agent activity
mTOR inhibitors	Multiple agents	mTOR	Under investigation	Being evaluated in preclinical and clinical studies	Dose-limiting toxicities, modest single-agent activity

Other Novel Therapeutic Targets: In addition to EGFR, immune checkpoints, and the PI3K/AKT/mTOR pathway, several other molecular targets are being explored for OSCC therapy. These include MEK inhibitors, STAT3 inhibitors, VEGFR inhibitors, dual tyrosine kinase inhibitors, and epigenetic modulators.

MEK Inhibitors (Table:5): The RAS/RAF/MEK/ERK pathway is frequently activated in OSCC, and MEK inhibitors have emerged as potential therapeutic agents. Trametinib, a selective MEK inhibitor, has been investigated in clinical trials for OSCC. A window-of-opportunity trial demonstrated that trametinib achieved significant tumor responses and reduced tumor proliferation markers in patients with locally advanced OSCC. These encouraging results warrant further clinical development of MEK inhibitors in OSCC, both as single agents and in combination with other therapies.

Table 5: MEK Inhibitors in OSCC

Drug/Agent	**Molecular Target**	**Clinical Trial Setting**	**Patient Population**	**Trial Design**	**Outcomes/ Results**	**Clinical Significance**
Trametinib	MEK	Neoadjuvant setting	Patients with locally advanced OSCC	Window-of-opportunity trial	Significant tumor responses; Reduction in tumor proliferation markers	Encouraging results demonstrated; Validates MEK as therapeutic target in OSCC

STAT3 Inhibitors (Table:6): Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates genes involved in cell proliferation, survival, angiogenesis, and immune evasion. STAT3 is constitutively activated in OSCC and represents an attractive therapeutic target. Multiple STAT3 inhibitors are under preclinical and early clinical development. However, developing specific and potent STAT3 inhibitors with favorable pharmacokinetic properties remains a challenge.

Table 6: STAT3 Inhibitors and Targeting Strategies in OSCC

Target	**Molecular Function**	**Alterations in OSCC**	**Therapeutic Implications**	**Development Status**
STAT3	Transcription factor regulating genes involved in cell proliferation, survival, angiogenesis, immune evasion	Constitutively activated in OSCC	Attractive therapeutic target	Multiple STAT3 inhibitors under preclinical and early clinical development

VEGFR Inhibitors (Table:7): Angiogenesis, the formation of new blood vessels, plays a critical role in tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are key mediators of angiogenesis and are overexpressed in OSCC. VEGFR inhibitors, including tyrosine kinase inhibitors and monoclonal antibodies, are being investigated as therapeutic agents for OSCC. Anti-angiogenic agents may normalize tumor vasculature, improve drug delivery, and enhance the efficacy of chemotherapy and radiotherapy.

Table 7: VEGFR Inhibitors in OSCC

Target	**Molecular Function**	**Role in OSCC**	**Therapeutic Approach**	**Development Status**	**Clinical Considerations**
VEGFR (Vascular Endothelial Growth Factor Receptor)	Mediates angiogenesis	Plays critical role in tumor angiogenesis and metastasis; VEGF and its receptors overexpressed in OSCC	VEGFR inhibitors (tyrosine kinase inhibitors, monoclonal antibodies)	Under investigation in OSCC	Anti-angiogenic agents may normalize tumor vasculature, improve drug delivery, enhance efficacy of chemotherapy and radiotherapy

Dual Tyrosine Kinase Inhibitors (Table:8): Dual tyrosine kinase inhibitors that simultaneously target multiple receptor tyrosine kinases are being explored as a strategy to overcome tumor heterogeneity and compensatory signaling mechanisms that contribute to resistance. Examples include agents that target both EGFR and VEGFR. By inhibiting multiple RTKs, these agents may provide broader inhibition of oncogenic signaling networks and potentially overcome the limitations of single-agent targeted therapies.

Table 8: Dual Tyrosine Kinase Inhibitors in OSCC

Inhibitor Type	**Target Receptors**	**Mechanism of Action**	**Rationale**	**Development Status**	**Potential Advantages**
Dual Tyrosine Kinase Inhibitors	Multiple RTKs simultaneously	Simultaneously inhibit multiple receptor tyrosine kinases	Address tumor heterogeneity and compensatory signaling mechanisms that contribute to resistance	Being explored	May overcome limitations of single-agent targeted therapies; Potentially more effective than single-target inhibitors

Epigenetic Modulators (Table:9): Epigenetic alterations, including aberrant DNA methylation, histone modifications, and chromatin remodeling, contribute to OSCC pathogenesis. These alterations can lead to silencing of tumor suppressor genes and activation of oncogenes. Epigenetic modulators, such as histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors, are being investigated as therapeutic agents for OSCC. These agents may restore normal gene expression patterns

and induce tumor cell differentiation or apoptosis. Combination of epigenetic modulators with conventional therapies or other targeted agents may enhance anti-tumor effects.

Table 9: Epigenetic Modulators in OSCC

Modulator Type	Molecular Targets	Epigenetic Alterations in OSCC	Mechanism of Action	Development Status	Therapeutic Potential
HDAC inhibitors	Histone deacetylases	DNA methylation, histone modification, chromatin remodeling	Inhibit histone deacetylases	Under investigation in preclinical and clinical studies	May restore normal gene expression patterns, induce tumor cell differentiation or apoptosis
DNA methyltransferase inhibitors	DNA methyltransferases	DNA methylation, histone modification, chromatin remodeling	Inhibit DNA methyltransferases	Under investigation in preclinical and clinical studies	May restore normal gene expression patterns, induce tumor cell differentiation or apoptosis

Clinical Trials and Outcomes (Table:10): Clinical trials have provided valuable insights into the efficacy and safety of emerging targeted therapies for OSCC. While several targeted agents have demonstrated clinical benefit, the outcomes have been variable, reflecting the complexity of OSCC biology and the challenges in patient selection.

EGFR inhibitors, particularly cetuximab, have shown improved overall survival when combined with radiotherapy or chemotherapy in patients with recurrent or metastatic HNSCC. However, response rates vary, and primary and acquired resistance remain significant challenges. The identification of predictive biomarkers to select patients most likely to benefit from EGFR inhibitors is an ongoing area of research.

Immune checkpoint inhibitors, including pembrolizumab and nivolumab, have demonstrated durable responses in a subset of patients with recurrent or metastatic HNSCC. However, response rates remain modest (approximately 15-20% in unselected populations), and the identification of predictive biomarkers beyond PD-L1 expression is critical for optimizing patient selection.

PI3K/AKT/mTOR pathway inhibitors have shown preclinical efficacy in OSCC models, but clinical trials have yielded modest single-agent activity, with dose-limiting toxicities limiting their clinical utility. Combination approaches are being explored to enhance efficacy and overcome resistance.

MEK inhibitors, such as trametinib, have shown encouraging results in neoadjuvant settings, with significant tumor responses observed in patients with locally advanced OSCC. Further clinical development is warranted to establish the role of MEK inhibitors in OSCC treatment.

Overall, clinical trials of targeted therapies for OSCC have highlighted the need for combination strategies, biomarker-driven patient selection, and personalized treatment approaches to improve outcomes.

Table 10: Clinical Trial Outcomes and Challenges

Trial Category/ Agent Type	Key Findings	Response Rates	Survival Benefits	Notable Challenges
EGFR Inhibitors (Cetuximab)	Improved overall survival when combined with radiotherapy or chemotherapy	Variable	Demonstrated survival improvement	Primary and acquired resistance; need for predictive biomarkers
Immune Checkpoint Inhibitors (Pembrolizumab, Nivolumab)	Durable responses in subset of patients	Modest (15-20% in unselected populations)	Improved survival in responders	Variable response rates; need for predictive

				biomarkers beyond PD-L1 expression
PI3K/AKT/mTOR Inhibitors	Preclinical efficacy demonstrated	Not specified	Modest single-agent activity	Dose-limiting toxicities; modest single-agent activity
MEK Inhibitors (Trametinib)	Significant tumor responses in neoadjuvant setting	Encouraging	Not fully established	Requires further clinical development

Challenges and Future Directions (Table:11): Despite significant progress in the development of targeted therapies for OSCC, several challenges must be addressed to fully realize their therapeutic potential. These challenges include resistance mechanisms, tumor heterogeneity, limited biomarker validation, and the need for personalized treatment strategies.

Resistance Mechanisms: Primary and acquired resistance to targeted therapies remain major obstacles. Resistance mechanisms include activation of alternative signaling pathways, mutations that reduce drug binding, and tumor evolution under selective pressure. Understanding these mechanisms and developing strategies to prevent or overcome resistance are critical priorities. Combination therapies that target multiple pathways simultaneously may help overcome resistance and improve treatment outcomes.

Tumor Heterogeneity: OSCC exhibits significant intra-tumoral and inter-tumoral heterogeneity, with different tumor cell populations harboring distinct molecular alterations. This heterogeneity poses challenges for single-agent targeted therapies, which may not effectively address all tumor cell populations. Combination approaches and personalized treatment strategies based on individual tumor molecular profiles may be necessary to overcome this challenge.

Biomarker Validation: The identification and validation of predictive biomarkers are essential for selecting patients most likely to benefit from targeted therapies. While several potential biomarkers have been identified, including EGFR expression, PD-L1 expression, and tumor mutational burden, their clinical utility remains limited. Robust biomarker validation studies and the integration of multi-omics approaches are needed to improve patient selection and treatment outcomes.

Drug Delivery: Achieving adequate drug concentrations at the tumor site while minimizing systemic toxicity remains a challenge. The development of novel drug delivery systems, such as nanoparticles, liposomes, and targeted delivery vehicles, may enhance the therapeutic efficacy of targeted agents and reduce off-target effects.

Combination Strategies: Combination therapies that integrate targeted agents with chemotherapy, radiotherapy, or immunotherapy are being actively explored. Rational combination strategies based on an understanding of molecular mechanisms and resistance pathways may enhance efficacy and overcome resistance. Identifying optimal combinations and sequencing of therapies is a key area of ongoing research.

Personalized Medicine: The heterogeneity of OSCC and the variable responses to targeted therapies underscore the need for personalized treatment approaches. Integration of genomic, transcriptomic, proteomic, and metabolomic data may facilitate the identification of patient subgroups most likely to benefit from specific therapies. The development of precision medicine approaches, including the use of patient-derived models and adaptive clinical trial designs, may improve treatment outcomes.

Future Directions: Future research should focus on understanding the molecular mechanisms underlying resistance to targeted therapies, validating predictive biomarkers, developing novel drug delivery systems, and exploring rational combination strategies. The integration of multi-omics approaches and artificial intelligence may facilitate the identification of novel therapeutic targets and the stratification of patients for personalized treatment. Collaborative efforts between researchers, clinicians, and pharmaceutical companies are essential to accelerate the translation of preclinical findings into clinical practice and improve outcomes for patients with OSCC.

Table 11: Challenges and Future Directions in OSCC Targeted Therapy

Challenge Category	Specific Issues	Future Direction/Solution	Expected Impact
Resistance Mechanisms	Primary and acquired resistance to targeted therapies; activation of alternative signaling pathways; tumor evolution under selective pressure	Combination therapies targeting multiple pathways; development of next-generation inhibitors; strategies to prevent or overcome resistance	Improved treatment efficacy; prolonged response duration
Tumor Heterogeneity	Intra-tumoral and inter-tumoral heterogeneity; single-agent targeted therapies may not effectively address all tumor cell populations	Combination approaches; personalized treatment strategies based on individual tumor molecular profiles	Better coverage of heterogeneous tumor populations
Biomarker Validation	Limited validated predictive biomarkers; patient selection remains challenging	Identification and validation of robust predictive biomarkers; multi-omics approaches for patient stratification	Improved patient selection; enhanced treatment outcomes
Drug Delivery	Challenges in achieving adequate drug concentrations at tumor site	Development of novel drug delivery systems (nanoparticles, liposomes, targeted delivery vehicles)	Enhanced therapeutic efficacy; reduced systemic toxicity
Combination Strategies	Need to identify optimal combinations and sequencing	Rational combination therapies (targeted agents with chemotherapy, radiotherapy, immunotherapy); investigation of synergistic combinations	Improved efficacy; overcome resistance mechanisms
Personalized Medicine	One-size-fits-all approach insufficient	Integration of genomic, transcriptomic, proteomic, metabolomic data; development of precision medicine approaches; patient stratification based on molecular profiles	Tailored treatment strategies; improved outcomes
Tumor Microenvironment	Role of tumor microenvironment in therapy resistance	Targeting tumor-stromal interactions; modulating immune microenvironment	Enhanced treatment efficacy
Clinical Trial Design	Need for innovative trial designs	Adaptive trial designs; basket and umbrella trials; incorporation of biomarker-driven patient selection	More efficient drug development; better patient outcomes

Conclusion

Targeted therapy represents a promising approach for improving outcomes in patients with oral squamous cell carcinoma. The molecular characterization of OSCC has revealed numerous dysregulated signaling pathways and potential therapeutic targets, leading to the development of a diverse array of targeted agents. EGFR inhibitors, immune checkpoint inhibitors, PI3K/AKT/mTOR pathway inhibitors, and other novel agents have demonstrated clinical activity in OSCC, offering new hope for patients with this challenging disease.

However, significant challenges remain, including primary and acquired resistance, tumor heterogeneity, limited biomarker validation, and the need for personalized treatment strategies. Overcoming these challenges will require a multifaceted approach, including the development of combination therapies, identification of predictive biomarkers, advancement of drug delivery systems, and integration of multi-omics approaches for patient stratification.

The future of OSCC treatment lies in precision medicine, where therapeutic decisions are guided by the molecular characteristics of individual tumors. Continued research efforts, collaborative partnerships, and innovative clinical trial designs will be essential to translate the promise of targeted therapies into improved outcomes for patients with OSCC. As our understanding of OSCC biology deepens and new therapeutic strategies emerge, there is reason for optimism that the prognosis for patients with this disease will continue to improve.

References

1. H. Sung et al., "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209-249, 2021.
2. F. Bray et al., "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394-424, 2018.
3. S. Warnakulasuriya, "Living with oral cancer: Epidemiology with particular reference to prevalence and life-style changes that influence survival," Oral Oncology, vol. 46, no. 6, pp. 407-410, 2010.
4. D. M. Parkin et al., "Global cancer statistics, 2002," CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74-108, 2005.
5. J. P. Shah and Z. Gil, "Current concepts in management of oral cancer–surgery," Oral Oncology, vol. 45, no. 4-5, pp. 394-401, 2009.
6. C. R. Leemans et al., "The molecular biology of head and neck cancer," Nature Reviews Cancer, vol. 11, no. 1, pp. 9-22, 2011.
7. Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas," Nature, vol. 517, no. 7536, pp. 576-582, 2015.
8. N. Stransky et al., "The mutational landscape of head and neck squamous cell carcinoma," Science, vol. 333, no. 6046, pp. 1157-1160, 2011.
9. J. R. Grandis and J. C. Tweardy, "Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer," Cancer Research, vol. 53, no. 15, pp. 3579-3584, 1993.
10. P. M. Specenier and J. B. Vermorken, "Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma," Expert Review of Anticancer Therapy, vol. 18, no. 9, pp. 901-915, 2018.
11. M. L. Gillison et al., "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers," Journal of the National Cancer Institute, vol. 92, no. 9, pp. 709-720, 2000.
12. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
13. N. Normanno et al., "Epidermal growth factor receptor (EGFR) signaling in cancer," Gene, vol. 366, no. 1, pp. 2-16, 2006.
14. D. A. Guertin and D. M. Sabatini, "Defining the role of mTOR in cancer," Cancer Cell, vol. 12, no. 1, pp. 9-22, 2007.
15. J. R. Grandis and D. J. Tweardy, "TGF-alpha and EGFR in head and neck cancer," Journal of Cellular Biochemistry, vol. 53, pp. 188-191, 1993.
16. K. K. Ang et al., "Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma," Cancer Research, vol. 62, no. 24, pp. 7350-7356, 2002.
17. J. A. Engelman, "Targeting PI3K signalling in cancer: opportunities, challenges and limitations," Nature Reviews Cancer, vol. 9, no. 8, pp. 550-562, 2009.
18. B. D. Manning and L. C. Cantley, "AKT/PKB signaling: navigating downstream," Cell, vol. 129, no. 7, pp. 1261-1274, 2007.
19. P. T. C. Wan et al., "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF," Cell, vol. 116, no. 6, pp. 855-867, 2004.
20. S. J. Bos, "ras oncogenes in human cancer: a review," Cancer Research, vol. 49, no. 17, pp. 4682-4689, 1989.
21. M. Olivier et al., "TP53 mutations in human cancers: origins, consequences, and clinical use," Cold Spring Harbor Perspectives in Biology, vol. 2, no. 1, p. a001008, 2010.
22. D. P. Lane, "Cancer. p53, guardian of the genome," Nature, vol. 358, no. 6381, pp. 15-16, 1992.
23. N. Katoh and M. Katoh, "Notch signaling in gastrointestinal tract (review)," International Journal of Oncology, vol. 30, no. 1, pp. 247-251, 2007.
24. S. Artavanis-Tsakonas et al., "Notch signaling: cell fate control and signal integration in development," Science, vol. 284, no. 5415, pp. 770-776, 1999.
25. S. L. Topalian et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
26. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy," Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
27. J. Mendelsohn and J. Baselga, "The EGF receptor family as targets for cancer therapy," Oncogene, vol. 19, no. 56, pp. 6550-6565, 2000.
28. R. Herbst and D. Langer, "Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers," Seminars in Oncology, vol. 29, no. 1, pp. 27-36, 2002.
29. J. B. Vermorken et al., "Platinum-based chemotherapy plus cetuximab in head and neck cancer," New England Journal of Medicine, vol. 359, no. 11, pp. 1116-1127, 2008.
30. K. J. Harrington et al., "Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib

monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study," Journal of Clinical Oncology, vol. 33, no. 35, pp. 4202-4209, 2015.
31. J. A. Bonner et al., "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck," New England Journal of Medicine, vol. 354, no. 6, pp. 567-578, 2006.
32. J. A. Bonner et al., "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival," Lancet Oncology, vol. 11, no. 1, pp. 21-28, 2010.
33. P. Kawczak et al., "Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma," Cancers, vol. 17, no. 17, p. 2805, 2025.
34. Y. Qi et al., "KLF7-Regulated ITGA2 as a Therapeutic Target for Inhibiting Oral Cancer Stem Cells," bioRxiv, 2024.
35. H. Hu et al., "Exploring the mechanism of Squamocin inhibits oral squamous cell carcinoma malignant progression by targeting peroxisome proliferator activated receptor," 2024.
36. L. Gao et al., "The pan-BH-3 mimetic, obatoclax, synergistically enhances cisplatin-induced apoptosis in oral squamous cell carcinoma through a mechanism that involves degradation of the pro-survival protein Mcl-1," Archives of Oral Biology, vol. 171, p. 106250, 2025.
37. Y. Zhang et al., "CircLDLRAD3 inhibits Oral squamous cell carcinoma progression by regulating miR-558/Smad4/TGF-β," Journal of Cellular and Molecular Medicine, vol. 27, no. 19, pp. 2891-2903, 2023.
38. S. Kumari et al., "Identification of therapeutically potential targets and their ligands for the treatment of OSCC," Frontiers in Oncology, vol. 12, p. 910494, 2022.
39. C. Juan et al., "Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma," Current Bioinformatics, vol. 15, no. 4, pp. 328-337, 2020.
40. Y. Liang et al., "Lipid homeostasis dysregulation in oral cancer drives metabolic reprogramming and offers novel diagnostic and therapeutic opportunities," Discover Oncology, vol. 16, p. 3299, 2025.
41. Y. Yang et al., "Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential," Expert Review of Anticancer Therapy, 2025.
42. W. Cao et al., "Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature," International Journal of Nanomedicine, vol. 17, pp. 4293-4336, 2022.
43. Y. Zhao et al., "The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges," International Journal of Surgery, 2026.
44. A. Singh et al., "Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies—A Review Article," Global Medical Genetics, vol. 9, no. 4, pp. 299-308, 2022.
45. T. Y. Li et al., "Current trends of targeted therapy for oral squamous cell carcinoma," Journal of Cancer Research and Clinical Oncology, vol. 148, no. 9, pp. 2169-2186, 2022.
46. X. Li et al., "Integrated Multi-Omics Analyses of Oral Squamous Cell Carcinoma Reveal Precision Patient Stratification and Personalized Treatment Strategies," SSRN, 2025.
47. F. C. Holsinger et al., "Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer," Clinical Cancer Research, vol. 9, no. 8, pp. 3183-3189, 2003.
48. X. Jiang et al., "STAT3 and its targeting inhibitors in oral squamous cell carcinoma," Cells, vol. 11, no. 19, p. 3131, 2022.
49. H. Hamakawa et al., "Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer," Head and Neck, vol. 30, no. 6, pp. 800-809, 2008.
50. R. Kaur et al., "Targeted Therapies in Oral and Oropharyngeal Cancer: An Overview of Emerging and Repurposed Agents," Cancers, vol. 17, no. 23, p. 3761, 2025.